PathoGenesis On Path To Profitability, Closes Up 20% In October
Executive Summary
PathoGenesis' ramp-up of Tobi inhaled tobramycin sales is winning the company an enthusiastic following on Wall Street.
You may also be interested in...
PathoGenesis Tobi Use Per Patient Can Be Raised About 50%, CEO Says
PathoGenesis believes that per patient use of Tobi inhaled tobramycin can be increased by about 50%.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011